Mayne Pharma Group Ltd.ASX: MYX

2025 Half Year Media Release

· Issued by Mayne Pharma Group Ltd.

Filed with ASX · · 7 pages · English

Summary by 6ix AI

The company reported a notable increase in underlying EBITDA and cash flow from continuing operations, reflecting a strong operational performance. Additionally, Mayne Pharma announced a scheme implementation deed with Cosette Pharmaceuticals for a proposed acquisition, valuing the company at a premium to its recent share price. The outlook remains positive, with expectations for continued revenue growth across its Women’s Health and Dermatology segments in the second half of the fiscal year.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Mayne Pharma Group Ltd. on 6ix

In the deck

Story so far

Earlier from Mayne Pharma

Later from Mayne Pharma

All Mayne Pharma news releases